Is there any guidance on upcoming clinical trial data or regulatory filings that could move the share price?

No explicit guidance in the release

The Webull webinar notice for Akari Therapeutics (AKRI) is purely an event reminder – it does not contain any forward‑looking statements about upcoming clinical‑trial read‑outs, data‑pak submissions, or regulatory filings. There is therefore no new, company‑provided catalyst in the news that would be expected to move the stock on its own.

What to watch for nonetheless

Akari’s recent pipeline updates (e.g., the Phase 2/3 programs for AKR-001 and AKR-002) have been the primary drivers of price action. If management uses the August 19 webcast to tease data milestones, discuss IND‑type filings, or hint at a forthcoming FDA meeting, the market could react sharply. Until such specifics are disclosed, the share price will continue to be guided by the existing technical picture and broader biotech sentiment.

Trading implications

- Short‑term: With no concrete catalyst, the stock is likely to trade on technical momentum and sector flow. Current price action around the August 19 window is best treated as a “hold‑or‑watch” scenario rather than a trigger for new positions.

- Medium‑term: Keep an eye on any post‑webinar transcript or press release that adds a timeline for trial data or an FDA filing. A clear timeline (e.g., “data expected Q4 2025” or “BLA filing in early 2026”) would create a directional move and could be used to set entry points on a breakout or pull‑back.

Actionable tip: Until the company issues explicit trial‑data or regulatory guidance, maintain a neutral stance. If the webcast yields a hint of a near‑term data read‑out, consider a short‑term long position on a breakout above the current resistance (≈ $0.90) with a stop just below the recent low (≈ $0.78). Conversely, a lack of new information may keep the stock in its existing range, favoring a wait‑and‑see approach.